Suven Pharmaceuticals Ltd.(IN:COHANCE)
₹457.45-1.10 (-0.24%)
IN:COHANCE
Suven Pharmaceuticals Ltd. financials statements
₹457.45
At close:-1.10 (-0.24%)
Want to see IN:COHANCE full AI Analyst Report?
Suven Pharmaceuticals Ltd. (COHANCE) Financial Statements
3 Followers
Suven Pharmaceuticals Ltd. Financial Overview
Suven Pharmaceuticals Ltd.'s market cap is currently ₹175.44B. The company's EPS TTM is ₹1.72; its P/E ratio is 267.09; and it has a dividend yield of 1.68%. Suven Pharmaceuticals Ltd. is estimated to report earnings on February 8, 2027, and the estimated EPS forecast is ₹0.91. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | ₹ 22.69B | ₹ 11.98B | ₹ 10.51B | ₹ 13.40B | ₹ 13.20B |
| Gross Profit | ₹ 9.11B | ₹ 8.22B | ₹ 6.80B | ₹ 7.52B | ₹ 7.46B |
| Operating Income | ₹ 2.40B | ₹ 5.66B | ₹ 5.40B | ₹ 6.30B | ₹ 6.33B |
| EBITDA | ₹ 4.32B | ₹ 4.06B | ₹ 4.09B | ₹ 5.73B | ₹ 5.80B |
| Net Income | ₹ 1.79B | ₹ 2.68B | ₹ 3.00B | ₹ 4.11B | ₹ 4.54B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | ₹ 3.26B | ₹ 2.90B | ₹ 8.21B | ₹ 4.84B | ₹ 5.26B |
| Total Assets | ₹ 57.30B | ₹ 30.32B | ₹ 22.54B | ₹ 19.66B | ₹ 18.30B |
| Total Debt | ₹ 4.00B | ₹ 2.79B | ₹ 649.96M | ₹ 703.41M | ₹ 971.27M |
| Net Debt | ₹ 3.41B | ₹ 1.94B | ₹ 177.65M | ₹ 55.38M | ₹ 525.63M |
| Total Liabilities | ₹ 16.96B | ₹ 11.91B | ₹ 2.03B | ₹ 2.31B | ₹ 3.02B |
| Stockholders' Equity | ₹ 39.11B | ₹ 16.97B | ₹ 20.51B | ₹ 17.35B | ₹ 15.27B |
| Cash Flow | |||||
| Free Cash Flow | ₹ 1.35B | ₹ 1.32B | ₹ 3.07B | ₹ 1.65B | ₹ 2.55B |
| Operating Cash Flow | ₹ 3.55B | ₹ 2.88B | ₹ 3.58B | ₹ 4.51B | ₹ 3.30B |
| Investing Cash Flow | ₹ -2.58B | ₹ -2.55B | ₹ -3.62B | ₹ -1.95B | ₹ -1.36B |
| Financing Cash Flow | ₹ -1.49B | ₹ 33.20M | ₹ -138.02M | ₹ -2.36B | ₹ -1.56B |
Currency in INR

